



News Release

FOR IMMEDIATE RELEASE

Contact: Ronald C. Trahan, APR, Ronald Trahan Associates Inc., (508) 359-4005, x108

**VasoGenix Pharmaceuticals elects Cleveland Clinic's
James Young, M.D., to its board of directors**

LENEXA, Kan., May 19, 2009—VasoGenix Pharmaceuticals announced today that heart failure/heart transplant cardiologist **James Young, M.D.**, has been elected to its board of directors. Dr. Young is Chairman of the Division of Medicine at the Cleveland Clinic and a professor in the Department of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.

In addition he is a Diplomate of the American Board of Internal Medicine and serves on the editorial boards of the *Journal of Heart and Lung Transplantation*, *American Heart Journal*, *Cleveland Clinic Journal of Medicine and Cardiology Today*, *Transplantation and Immunology Letter*, and *The Canadian Journal of Cardiology*. He has nearly 600 publications to his credit; has edited or co-edited, authored or co-authored 23 books on heart failure; published and presented 508 abstracts; and has 47 multi-center clinical trial publications.

“We welcome Dr. James Young to our board. With Jim’s vast experience in the clinical aspects of heart failure and his long association with the Cleveland Clinic, America’s number-one heart hospital, he will be invaluable to VasoGenix Pharmaceuticals in the development of our new CGRP (calcitonin gene related peptide) agonist analogs to treat heart failure,” said **G. Lee Southard, Ph.D.**, Chairman and CEO of VasoGenix Pharmaceuticals.

In accepting his appointment Dr. Young said, “It is an exciting time to be in heart failure research, and VasoGenix is a forward-looking company with its lead h- α -CGRP analog combined with a biodegradable, controlled-release method of delivery. The company’s vision to enhance the quality of life of heart failure patients while impacting the cost of treatment by reducing hospitalization time and rates of readmission is consistent with the critical needs we have in heart failure now and in the future.”

VasoGenix Pharmaceuticals is a privately held, emerging bio-pharmaceutical company focused on developing an agonist analog of ‘CGRP’ (calcitonin gene related peptide) as a primary treatment for heart failure and growing through exploitation of its series of synthetic agonist CGRP analogs for other cardiovascular, renal and respiratory diseases. The company plans to implement investor-beneficial exit strategies following disease specific proof-of-concept.

Statements contained in this press release, which are not historical facts, are forward-looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by the use of words such as, “expects,” “plans,” “estimates,” “projects,” “promises,” “intends,” “believes,” and similar expressions that do not relate to historical matters. Such forward-looking statements are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated, due to a number of factors, which include, but are not limited to, to identify strategic partners or, if identified, the inability to enter into an acceptable agreement with such strategic partners and successfully concluding the development and regulatory processes. All forward-looking statements in this press release are made as of today, based upon information known to management as of the date hereof. VasoGenix assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that indicated results or events will not be realized.

#